Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
Clave, P. 1,2,3; Acalovschi, M. 4; Triantafillidis, J. K. 5; Uspensky, Y. P. 6; Kalayci, C. 7; Shee, V. 8; Tack, J. 9; on behalf of the OBIS Study Investigators
Alimentary Pharmacology & Therapeutics.
34(4):432-442, August 2011.
(Format: HTML, PDF)